RecruitingNCT05621837
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Enrollment
1,000 participants
Start Date
Mar 10, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria7
- Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included
- Will and ability to comply with the protocol
- Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis
- Age from 18 to 90 years at the time of recruitment
- ECOG Performance Status \<= 2
- Understanding and signature of the informed consent
- Consenting to participate to the socio-economical-psychological survey
Exclusion Criteria5
- Known history of HIV infection
- Serious neurological or psychiatric disorders
- Pregnancy or lactation
- Inability or unwillingness of participant to give written informed consent
- Inability or unwillingness to be regularly followed up at the same center
Interventions
OTHERMDSC quantification
Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05621837
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NCT0407709940 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT0711504311 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations